Blocking IL-17A Promotes the Resolution of Pulmonary Inflammation and Fibrosis Via TGF-β1–Dependent and –Independent Mechanisms
Open Access
- 15 September 2011
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 187 (6), 3003-3014
- https://doi.org/10.4049/jimmunol.1004081
Abstract
Pulmonary fibrosis is the pathologic basis for a variety of incurable human chronic lung diseases. IL-17A, a glycoprotein secreted from IL-17–producing cells, has recently been shown to be a proinflammatory cytokine involved in chronic inflammation and autoimmune disease. In this study, we report that IL-17A increased the synthesis and secretion of collagen and promoted the epithelial–mesenchymal transition in alveolar epithelial cells in a TGF-β1–dependent manner. Using in vivo fibrotic models, we found IL-17A expression to be elevated and IL-17A–associated signaling pathways to be activated in fibrotic lung tissues. Neutralization of IL-17A in vivo promoted the resolution of bleomycin-induced acute inflammation, attenuated pulmonary fibrosis, and increased survival. Additionally, IL-17A antagonism inhibited silica-induced chronic inflammation and pulmonary fibrosis. Targeting IL-17A resulted in a shift of the suppressive immune response in fibrotic lung tissue toward a Th1-type immune response, and it effectively induced autophagy, which promoted the autophagic degradation of collagen and autophagy-associated cell death. Moreover, IL-17A was found to attenuate the starvation-induced autophagy, and autophagy modulators regulated collagen degradation in the alveolar epithelial cells in a TGF-β1–independent manner. Administration of 3-methylamphetamine, an autophagy inhibitor, reversed the therapeutic efficacy of IL-17A antagonism in pulmonary fibrosis. Our studies indicate that IL-17A participates in the development and progression of pulmonary fibrosis in both TGF-β1–dependent and –independent manners and that the components of the IL-17A signaling pathway are potential therapeutic targets for the treatment of fibroproliferative lung diseases.This publication has 38 references indexed in Scilit:
- Scraping fibrosis: Expressway to the core of fibrosisNature Medicine, 2011
- Blockade of Interleukin-17A Results in Reduced Atherosclerosis in Apolipoprotein E–Deficient MiceCirculation, 2010
- Extracellular matrix remodeling in atrial fibrosis: Mechanisms and implications in atrial fibrillationJournal of Molecular and Cellular Cardiology, 2010
- Nonresolving InflammationCell, 2010
- Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependentThe Journal of Experimental Medicine, 2010
- Methods in Mammalian Autophagy ResearchCell, 2010
- Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophagesJCI Insight, 2009
- Epithelial-Mesenchymal Transitions in Development and DiseaseCell, 2009
- Autophagy Suppresses Tumorigenesis through Elimination of p62Cell, 2009
- Cellular and molecular mechanisms of fibrosisThe Journal of Pathology, 2007